1. Amelioration of Murine Macrophage Activation Syndrome by Monomethyl Fumarate in Both a Heme Oxygenase 1-Dependent and Heme Oxygenase 1-Independent Manner.
- Author
-
Biswas C, Chu N, Burn TN, Kreiger PA, and Behrens EM
- Subjects
- Animals, Cytokines immunology, Disease Models, Animal, Heme Oxygenase-1 genetics, Heme Oxygenase-1 metabolism, Interleukin-10 immunology, Liver drug effects, Liver pathology, Macrophage Activation Syndrome metabolism, Macrophage Activation Syndrome pathology, Macrophages immunology, Macrophages metabolism, Membrane Proteins genetics, Membrane Proteins metabolism, Mice, Mice, Knockout, Oligodeoxyribonucleotides pharmacology, Organ Size drug effects, Spleen drug effects, Spleen pathology, Toll-Like Receptor 9 agonists, Cytokines drug effects, Fumarates pharmacology, Heme Oxygenase-1 drug effects, Macrophage Activation Syndrome immunology, Macrophages drug effects, Membrane Proteins drug effects
- Abstract
Objective: Macrophage activation syndrome (MAS) is characterized by increased serum levels of ferritin and heme oxygenase 1 (HO-1), and yet no known function is ascribed to these molecules in MAS. Because HO-1 is antiinflammatory, we hypothesized that pharmacologic activation of HO-1 could ameliorate MAS disease activity. Dimethyl fumarate (DMF), a treatment approved by the US Food and Drug Administration for multiple sclerosis, activates HO-1. Monomethyl fumarate (MMF) is the active metabolite of DMF. We therefore evaluated whether MMF could elicit HO-1-dependent therapeutic improvements in a murine model of MAS., Methods: We induced MAS by repeated activation of Toll-like receptor 9 (TLR-9) in wild-type and myeloid-specific HO-1-deficient mice. MMF was administered twice daily to test its efficacy. We assessed organ weights, serum cytokine levels, histologic features of the spleen and liver tissue, and complete blood cell counts to evaluate disease activity. Statistical testing was performed using Student's t-test or by 2-way analysis of variance as appropriate., Results: The presence of HO-1 was required for the majority of TLR-9-induced interleukin-10 (IL-10). IL-10 production in TLR-9-induced MAS was found to correlate with the myeloid-HO-1 gene dose in myeloid cells (P < 0.001). MMF treatment increased the levels of HO-1 in splenic macrophages by ~2-fold (P < 0.01), increased serum levels of IL-10 in an HO-1-dependent manner in mice with TLR-9-induced MAS (P < 0.005), and improved multiple disease parameters in both an HO-1-dependent and HO-1-independent manner., Conclusion: TLR-9-induced production of IL-10 is regulated by HO-1 activity both in vitro and in vivo. Therapeutic enhancement of the HO-1/IL-10 axis in a murine model was able to significantly ameliorate MAS disease activity. These results suggest that HO-1 may be viable as a MAS therapeutic target, and treatment with DMF and MMF should be considered in future investigations of MAS therapy., (© 2020, American College of Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF